The EU-funded ECRAID-Base project received additional financial support from the European Health Data & Evidence Network (EHDEN) and HSBooster.eu. The grants with a combined value of 80,000 euro will go towards enhancing opportunities for secure data reuse and implementation of FAIR principles within ECRAID-Base and beyond with a focus on ventilator-associated pneumonia, antimicrobial resistance, and microbiology laboratory data. POS-VAP and POS-Disease X will be the first studies to benefit from these important developments.
ECRAID-Base has received 70,000 euro from the European Health Data & Evidence Network (EHDEN) to extend the project’s FAIR-by-design approach. The grant will allow the Data team to translate the electronic case report form (eCRF) for the perpetual observational study (POS) on ventilator-associated pneumonia (VAP) from the CDISC standard to the Observational Medical Outcomes Partnership common data model (OMOP CDM) based on SNOMED and LOINC standardised terminologies.
The project has partnered with edenceHealth NV to map the POS-VAP study variables from CDISC to OMOP CDM and ensure that ECRAID-Base can participate in the Observational Health Data Sciences and Informatics (OHDSI) community. OHDSI is an open-source, grass-roots, global effort to maximise the return on data through building interoperability within and across health data sources. The OHDSI approach allows for cross-site analyses without moving or directly accessing participant-level health data, which addresses ethical and legal barriers to reusing health data while fast-tracking data reuse.
Generating "FAIR by design" data and samples is a central objective of ECRAID-Base. Because OMOP CDM is widely used in hospital settings, the transformation of the ECRAID-Base POS-VAP eCRF from CDISC into OMOP CDM will enable joint analysis between hospital- and health system-based data, including the European Health Data Space (EHDS) and country-level health data spaces, and clinical trials, which use the CDISC standard.
Improving the detection and response to antimicrobial resistance (AMR) is a cross-cutting theme for ECRAID-Base’s five POSs, and the POS-VAP eCRF includes a large microbiological identification and susceptibility testing section. Mapping these AMR-related variables from CDISC into OMOP CDM helps ECRAID-Base improve the detection and response to AMR within the project and beyond.
How studies implement the FAIR principles has important implications for data reuse. By building out ECRAID-Base’s FAIR-by-design eCRF for the POS-VAP study in OMOP CDM, the consortium is working to extend the state of the art and build FAIR in the field of ventilator-associated pneumonia and AMR.
ECRAID-Base is actively seeking funding to continue our collaboration with edenceHealth NV and build FAIR by creating crosswalks between CDISC and OMOP CDM for the four other POSs.
An additional 10,000 euro of seed funding from HSBooster.eu will allow ECRAID-Base to begin working towards transforming unstructured microbiology laboratory data into HL7 FHIR. In close collaboration with Institute of Biomedicine Seville (IBIS), the project will identify pathways for making unstructured microbiology data from hospitals that partner with Erasmus MC for a POS on (re)emerging pathogens (POS-Disease X) interoperable.
ECRAID-Base uses the "FAIR by design" approach to maximise data and sample utility. Because HL7 FHIR is widely used in Real-world data (RWD), the transformation of unstructured microbiology data from POS-Disease X partner sites into HL7 FHIR will facilitate the rapid reuse of data in the research response to (re)emerging pathogens. ECRAID-Base sees this seed funding as an important first step towards improving FAIR implementation and fast-tracking the reuse of participant-level data and samples in clinical investigations of (re)emerging pathogens.
About our funding partners
The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
edenceHealth provides analysis and IT services to people and organizations that work with Real World Evidence (RWE). Among one of the first certified SMEs for the EHDEN project, edenceHealth is an expert in delivering well-structured solutions for data partners that seamlessly transform real world clinical data into decision-making evidence.
HSbooster.eu, a Coordination and Support Action funded by the European Commission under the Horizon Europe framework, aims at boosting the entire European Standardisation dialogue between Horizon 2020 and Horizon Europe projects with corresponding Standards Developing Organisations (SDOs) to increase the European impact on (international) standardisation and strengthen the European competitiveness. The HSBooster.eu Premium Services Programme (Grant Agreement 101058391) provides funding to standardisation experts to support EC-funded projects reach their standardisation goals.
Institute of Biomedicine of Seville (IBIS)
IBIS is a multidisciplinary biomedical research center, with the aim to undertake high quality and competitive research at international level on the most prevalent diseases and the development of new methods of diagnosis and treatment.